These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 29879234)

  • 1. Newer cholesterol-lowering agents: What you must know.
    Firnhaber JM
    J Fam Pract; 2018 Jun; 67(6):339;341;344;345. PubMed ID: 29879234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia.
    Karalis DG; Mallya UG; Ghannam AF; Elassal J; Gupta R; Boklage SH
    Am J Cardiol; 2018 May; 121(10):1155-1161. PubMed ID: 29548678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target.
    Sabatine MS; Giugliano RP
    JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310
    [No Abstract]   [Full Text] [Related]  

  • 5. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
    Leong D; Wu PE
    CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
    [No Abstract]   [Full Text] [Related]  

  • 6. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
    Cervelli N; Tocci G; Ferri C
    High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
    Lloyd-Jones DM
    JAMA Cardiol; 2017 Sep; 2(9):937-938. PubMed ID: 28768306
    [No Abstract]   [Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
    Ortega Martínez de Victoria E
    Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study.
    Miyoshi T; Nakamura K; Doi M; Ito H
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):213-9. PubMed ID: 25896669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
    Lüscher TF
    Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis.
    Weitz JI; Fazio S
    Circ Res; 2019 Feb; 124(3):351-353. PubMed ID: 30702992
    [No Abstract]   [Full Text] [Related]  

  • 15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Drugs for Lowering LDL-Cholesterol.
    Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
    Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
    Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
    Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know.
    Jia X; Al Rifai M; Birnbaum Y; Smith SC; Virani SS
    Curr Atheroscler Rep; 2019 Apr; 21(6):20. PubMed ID: 30941517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.
    Betteridge DJ
    Nat Rev Endocrinol; 2013 Feb; 9(2):76-8. PubMed ID: 23296165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.